Publications by authors named "Fady Botros"

Claim this Profile
E
Electrocardiographic changes in transgender patients on gender-affirming hormone replacement therapy.
Heather M Wang, Meet S Shah, Rafael E Toro-Manotas, Shriya D Patel, Fady Botros

J Electrocardiol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From zero- to few-shot: deep temporal learning of wrist EMG enables scalable cross-user gesture recognition.
Fady S Botros, Heather E Williams, Angkoon Phinyomark, Erik J Scheme

J Neural Eng· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-weekly insulin efsitora alfa: Design and rationale for the QWINT phase 3 clinical development programme.
Richard M Bergenstal, Athena Philis-Tsimikas, Carol Wysham, Molly C Carr, Juliana M Bue-Valleskey, Fady T Botros

Diabetes Obes Metab· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dulaglutide and Kidney Function-Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis.
Fady T Botros, Hertzel C Gerstein, Raleigh Malik, Claudia Nicolay, Anastasia Hoover

Diabetes Care· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indicators of Kidney Fibrosis in Patients with Type 2 Diabetes and Chronic Kidney Disease Treated with Dulaglutide.
Katherine R Tuttle, Jonathan Matthew Wilson, Yanzhu Lin, Hui-Rong Qian, Federica Genovese, Fady T Botros

Am J Nephrol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial.
Edward Franek, Hertzel C Gerstein, Matthew C Riddle, Claudia Nicolay, Ana Hickey, Fady T Botros

Diabetes Obes Metab· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A thrombin-PAR1/2 feedback loop amplifies thromboinflammatory endothelial responses to the viral RNA analogue poly(I:C).
Saravanan Subramaniam, Yamini Ogoti, Irene Hernandez, Mark Zogg, Fady Botros

Blood Adv· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Follow-up of SARS-CoV-2 positive subgroup from the Asymptomatic novel CORonavirus iNFection study.
Kristin J Meyers, Brian Dillman, Charles Williams, Jianfei Jiang, Nancy Clifford, Fady T Botros

J Med Virol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcomes by Albuminuria Status with Dulaglutide versus Insulin Glargine in Participants with Diabetes and CKD: AWARD-7 Exploratory Analysis.
Katherine R Tuttle, Brian Rayner, Mark C Lakshmanan, Anita Y M Kwan, Manige Konig, Fady T Botros

Kidney360· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A cross-sectional community-based observational study of asymptomatic SARS-CoV-2 prevalence in the greater Indianapolis area.
Kristin J Meyers, Meghan E Jones, Iris A Goetz, Fady T Botros, Jack Knorr

J Med Virol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial.
Hertzel C Gerstein, Robert Hart, Helen M Colhoun, Rafael Diaz, Mark Lakshmanan, Fady T Botros

Lancet Diabetes Endocrinol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, Rafael Diaz, Mark Lakshmanan, Fady T Botros

Lancet· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7).
Katherine R Tuttle, Mark C Lakshmanan, Brian Rayner, Alan G Zimmermann, Brad Woodward, Fady T Botros

Diabetes Obes Metab· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The association between the severity of chronic kidney disease and medical costs among patients with type 2 diabetes.
Maureen J Lage, Kristina S Boye, Jay Patrick Bae, Jianmin Wu, Reema Mody, Fady T Botros

J Med Econ· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GLP-1 receptor agonists, CKD, and eGFR trajectory - Authors' reply.
Katherine R Tuttle, Mark C Lakshmanan, Brian Rayner, Robert S Busch, Alan G Zimmermann, Fady T Botros

Lancet Diabetes Endocrinol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme.
Chantal Mathieu, Stefano Del Prato, Fady T Botros, Vivian T Thieu, Imre Pavo

Diabetes Obes Metab· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
Katherine R Tuttle, Mark C Lakshmanan, Brian Rayner, Robert S Busch, Alan G Zimmermann, Fady T Botros

Lancet Diabetes Endocrinol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Dulaglutide and Insulin Glargine on Estimated Glomerular Filtration Rate in a Real-world Setting.
Kristina S Boye, Reema Mody, Jianmin Wu, Maureen J Lage, Fady T Botros

Clin Ther· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression of novel "LOCGEF" isoforms of ARHGEF18 in eosinophils.
Keren B Turton, Emily M Wilkerson, Alex S Hebert, Frances J Fogerty, Hazel M Schira, Fady E Botros

J Leukoc Biol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glucagon-Like Peptide-1 Receptor Agonist Use and Renal Impairment: A Retrospective Analysis of an Electronic Health Records Database in the U.S. Population.
Kristina S Boye, Fady T Botros, Axel Haupt, Brad Woodward, Maureen J Lage

Diabetes Ther· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials.
Katherine R Tuttle, T Dwight McKinney, Jaime A Davidson, Greg Anglin, Kristine D Harper, Fady T Botros

Diabetes Obes Metab· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline factors associated with glycaemic response to treatment with once-weekly dulaglutide in patients with type 2 diabetes.
Carol Wysham, Bruno Guerci, David D'Alessio, Nan Jia, Fady T Botros

Diabetes Obes Metab· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program.
Johan Jendle, George Grunberger, Thomas Blevins, Francesco Giorgino, Ryan T Hietpas, Fady T Botros

Diabetes Metab Res Rev· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
Keith C Ferdinand, Fady T Botros, Charles M Atisso, Philip T Sager

Cardiovasc Diabetol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EPCR-dependent PAR2 activation by the blood coagulation initiation complex regulates LPS-triggered interferon responses in mice.
Hai Po H Liang, Edward J Kerschen, Irene Hernandez, Sreemanti Basu, Mark Zogg, Fady Botros

Blood· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis